Apatinib Mesylate is named as a drug or biological intervention in 11 clinical trials in our China trial register, 7 of which are recruiting. Lead sponsors include The First Affiliated Hospital of Bengbu Medical University (2), Fujian Cancer Hospital (1) and Zhejiang University (1). Registered phases: Phase 2, Phase 3, Phase 1/2, Phase 2/3 and Not applicable. Conditions studied include Hepatocellular Carcinoma; Immunotherapy; Gastric Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Hepatocellular Carcinoma | 2 |
| Immunotherapy | 2 |
| Gastric Cancer | 2 |
| Advanced Triple Negative Breast Cancer | 1 |
| Triple-negative Breast Cancer | 1 |
| Metastatic Pancreatic Carcinoma | 1 |
| Molecular Targeted Therapy | 1 |
| Preoperative | 1 |
| Small Cell Lung Cancer Limited Stage | 1 |
| Small Cell Lung Carcinoma | 1 |
| Fludzoparib" and Anti-angiogenic | 1 |
| HRD-positive/HER2-negative Advanced Breast Cancer | 1 |
| Apatinib | 1 |
| Biomarker | 1 |
| Recurrent Atypical/malignant Meningioma | 1 |
| Surgery | 1 |
| Lead sponsor | Trials |
|---|---|
| The First Affiliated Hospital of Bengbu Medical University | 2 |
| Fujian Cancer Hospital | 1 |
| Zhejiang University | 1 |
| Shanghai Zhongshan Hospital | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
| Jin Ying | 1 |
| Peking University Cancer Hospital & Institute | 1 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
| Beijing Sanbo Brain Hospital | 1 |
| Fujian Medical University | 1 |
| Register | Apatinib Mesylate trials |
|---|---|
| Clinical trials in China | 11 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Apatinib Mesylate works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Apatinib Mesylate (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.